Tesamorelin vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | KPV |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |